Scrip
Priority review status is still a worthwhile aim
28 September 2009
Peter Charlish
What’s the best strategy to adopt when seeking FDA approval for a new pharmaceutical product? In these straitened times, can companies justify going beyond the basic requirements of the relevant legislation, or is it worth pulling out all the stops and aiming to compile a ‘super dossier’ no matter what...
Please Login to read the full article.
28 September 2009
Peter Charlish
Please Login to read the full article.
RELATED CONTENT
NEWS
- Actelion needs to provide more info to FDA for Zavesca in Niemann-Pick disease
- FDA advisory committee recommends approval of miglustat in Niemann-Pick disease
- Daiichi Sankyo raises interim profit outlook after first-half loss
- Lundbeck's antipsychotic Serdolect safe for some patients, US panel says
EVENTS
17 March 2010
Berlin, Germany
17 March 2010
Berlin, Germany
22 March 2010
London, UK
JOB OF THE WEEK
Promote your vacancy here
DIRECTORY
Scrip Directory 2009
